Amneal Pharmaceuticals, Inc. AMRX Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Amneal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The official record: Amneal Pharmaceuticals, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Amneal Pharmaceuticals, Inc.'s financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Amneal Pharmaceuticals, Inc.'s financing cash flow?
- Amneal Pharmaceuticals, Inc. (AMRX) reported financing cash flow of -$59.06M in Q1 2026.
- How has Amneal Pharmaceuticals, Inc.'s financing cash flow changed year-over-year?
- Amneal Pharmaceuticals, Inc.'s financing cash flow decreased by 50.8% year-over-year, from -$39.17M to -$59.06M.
- What is the long-term trend for Amneal Pharmaceuticals, Inc.'s financing cash flow?
- Over 2 years (2021 to 2024), Amneal Pharmaceuticals, Inc.'s financing cash flow has grown at a 23.8% compound annual growth rate (CAGR), from -$138.12M to -$211.79M.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.